Cholecystokinin peptides in cerebrospinal fluid: A study in healthy male subjects lumbar-punctured without preceding strict bed-rest

Journal of Neural Transmission

Volumn 106, Issue 3-4, 1999, Pages 275-282

  Gunnarsson, T ^a,b   Eklundh, T ^a   Eriksson, M ^a   Sjoberg S ^a   Nordin, C ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atmospheric pressure; CCK 4; CCK 8; Cerebrospinal fluid

Indexed keywords

CHOLECYSTOKININ;

ADULT; ARTICLE; ATMOSPHERIC PRESSURE; BED REST; BODY POSITION; CEREBROSPINAL FLUID; HUMAN; HUMAN EXPERIMENT; LUMBAR PUNCTURE; MALE; NERVE FIBER; NORMAL HUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ADULT; ATMOSPHERIC PRESSURE; BED REST; HUMANS; MALE; OSMOLAR CONCENTRATION; REFERENCE VALUES; SINCALIDE; SPINAL PUNCTURE; SUPINE POSITION; TETRAGASTRIN; TIME FACTORS;

EID: 0032918999     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050157     Document Type: Article

References (25)

1. Albus M (1988) Cholecystokinin. Prog Neuropsychopharmacol Biol Psychiatry 12: S5-S21
2. Bednar I, Forsberg G, Lindén A, Qureshi GA, Södersten P (1991) Involvement of dopamine in inhibition of food intake by cholecystokinin octapeptide in male rats. J Neuroendocrinol 3(5): 491-496
3. Bertilsson L, Åberg M (1984) Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: Methodological aspects, In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in Biochemical and Pharmacological Research in Depression. Raven Press, New York, pp 27-34
4. Bowers M, Gerbode FA (1968) Relationship of monoamine metabolites in human cerebrospinal fluid to age. Nature 219: 1256-1257
5. Bradwejn J, Koszycki D (1994a) The cholecystokinin hypothesis of anxiety and panic disorder. In: Reeve Jr VEJR, Solomon TE, Go VLW (eds) Cholecystokinin. NY Acad Sci 713: 273-282
6. Bradwejn J, Koszycki D (1994b) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151: 261-263
7. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48: 603-610
8. Bradwejn J, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H, Annable L (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51: 486-493
9. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A (1995) Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38: 742-746
10. de Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46: 511-517
11. Eklundh T, Fernström V, Nordin C (1994) Influence of tapping-time and atmospheric pressure on concentrations of monoamine metabolites in the cerebrospinal fluid: A prospective study in female volunteers. J Psychiatr Res 28: 511-517
12. Eklundh T, Eriksson M, Sjöberg S, Nordin C (1996) Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: A prospective study in healthy male subjects. J Psychiatr Res 30: 201-208
13. Gunnarsson T, Eklundh T, Eriksson M, Qureshi GA, Sjöberg S, Nordin C (1997) Cholecystokinin peptides in cerebrospinal fluid: A study in healthy male subjects. Regul Pept 68: 57-61
14. Kleinbaum DG, Kupper LL, Muller KE (1988) Applied Regression Analyses and Other Multivariable Methods. PWS-KENT Publishing Company, Boston
15. Koszycki D, Zacharko RM, Le Melledo J-M, Young SN, Bradwejn J (1996) Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40: 648-655
16. Le Melledo J-M, Bradwejn J, Koszycki D, Bichet D (1995) Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry 52: 605-606
17. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC (1992) CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 149: 691-693
18. Lydiard RB, Brewerton TD, Fossey MD, Laraia MT, Stuart G, Beinfeld MC, Ballenger JC (1993) CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry 150: 1099-1101
19. Löfberg C, Harro J, Gottfries C-G, Oreland L (1996) Cholecystokinin peptides and receptor binding in Alzheimer's disease. J Neural Transm 103: 851-860
20. Nordin C, Swedin A, Zachau AC (1993) Tapping-time influences concentrations of 5-HIAA in the CSF. J Psychiatr Res 27: 409-414
21. Nordin C, Eklundh T, Fernström V, Swedin A, Zachau AC (1995) Gradients of CSF monoamine metabolites: A comparison between male and female volunteers. J Psychiatr Res 29: 133-140
22. Pittaway KM, Hill RG (1987) Cholecystokinin and pain. Pain Headache 9: 213-246
23. Qureshi GA, Bednar I, Min Q, Södersten P, Silberring J, Nyberg F, Thörnwall M (1993) Quantitation anal identification of two cholecystokinin peptides. CCK-4 and CCK-8s, in rat brain by HPLC anal fast atom bombardment mass spectrometry. Biom Chromatogr 7: 251-255
24. Rex A, Fink H, Marsden CA (1994) Effects of BOC-CCK-4 and L-365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 33: 559-565
25. Vasar E, Peuranen E, Ööpik T, Harro J, Männistö PT (1993) Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 110: 213-218